Migraine therapy: Development and testing of a patient preference questionnaire

被引:27
作者
Caro, G
Caro, JJ
O'Brien, JA
Anton, S
Jackson, J
机构
[1] Caro Res, Montreal, PQ, Canada
[2] McGill Univ, Div Internal Med, Montreal, PQ, Canada
[3] Bristol Myers Squibb, Wallingford, CT USA
来源
HEADACHE | 1998年 / 38卷 / 08期
关键词
migraine; patient preference; questionnaires; outcomes; efficacy measures;
D O I
10.1046/j.1526-4610.1998.3808602.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives.-To develop and test a patient preference questionnaire in migraine. Methods.-A user-friendly, self-administered questionnaire was developed to assess the relative importance of aspects of migraine therapy to patients. It was tested in a convenience sample of 66 migraineurs. The questionnaire has five sections: patient preference, migraine history, demographics, usual behavior during an attack, and migraine impact on cognition and functionality. It employs a special reverse-ranking technique to quantify preferences. Results.-Sixty-six migraineurs participated: 86% were women, 53% had not consulted their doctor about migraine in the previous year; and only 51% took prescribed medication, the majority (52%) at the start of a migraine. "A medication that can be taken any time during a migraine attack" was ranked most important by 20% of the migraineurs, one that decreases pain from the unbearable level in 30 minutes by 17%, and one that relieves pain completely within 2 hours by 15%. Not being able to think or concentrate with severe symptoms was reported by 71%. Optional activities were impeded by migraine in 83% of subjects, but required activities in only 60%. Conclusions.-The patient preference questionnaire is readily completed by subjects and reveals that the dimensions of relief preferred by patients can be addressed by a self-report questionnaire.
引用
收藏
页码:602 / 607
页数:6
相关论文
共 16 条
[1]   TREATMENT OF ACUTE MIGRAINE WITH SUBCUTANEOUS SUMATRIPTAN [J].
CADY, RK ;
WENDT, JK ;
KIRCHNER, JR ;
SARGENT, JD ;
ROTHROCK, JF ;
SKAGGS, H .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (21) :2831-2835
[2]  
CHAPMAN AH, 1978, TREATMENT TECHNIQUES
[3]   MIGRAINE PATIENTS EXPERIENCE POORER SUBJECTIVE WELL-BEING/QUALITY OF LIFE EVEN BETWEEN ATTACKS [J].
DAHLOF, CGH ;
DIMENAS, E .
CEPHALALGIA, 1995, 15 (01) :31-36
[4]   SUMATRIPTAN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN THE ACUTE TREATMENT OF MIGRAINE AND CLUSTER HEADACHE [J].
DECHANT, KL ;
CLISSOLD, SP .
DRUGS, 1992, 43 (05) :776-798
[5]  
FORGUS R, 1979, PERSONALITY COGNITIV
[6]   A CRITICAL-APPRAISAL OF THE QUALITY OF QUALITY-OF-LIFE MEASUREMENTS [J].
GILL, TM ;
FEINSTEIN, AR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (08) :619-626
[7]   DEVELOPMENT OF A BRIEF 24-HOUR MIGRAINE-SPECIFIC QUALITY-OF-LIFE QUESTIONNAIRE [J].
HARTMAIER, SL ;
SANTANELLO, NC ;
EPSTEIN, RS ;
SILBERSTEIN, SD .
HEADACHE, 1995, 35 (06) :320-329
[8]   A POPULATION-BASED SURVEY OF THE SOCIAL AND PERSONAL IMPACT OF HEADACHE [J].
KRYST, S ;
SCHERL, E .
HEADACHE, 1994, 34 (06) :344-350
[9]  
LUCIANI RJ, 1995, J FAM PRACTICE, V41, P147
[10]   MEASURING THE FUNCTIONAL STATUS AND WELL-BEING OF PATIENTS WITH MIGRAINE HEADACHE [J].
OSTERHAUS, JT ;
TOWNSEND, RJ ;
GANDEK, B ;
WARE, JE .
HEADACHE, 1994, 34 (06) :337-343